商品名：Antirobe, Clindrops, Clindarobe, Clintabs, Clinsol, and
Antibacterial drug of the lincosamide class (similar in action to macrolides). It shares structural, microbiologic activity, and other properties with lincomycin. It inhibits bacterial protein synthesis via inhibition of bacterial ribosome. Clindamycin is bacteriostatic with a spectrum of activity primarily against gram-positive bacteria and anaerobes. Clindamycin, like the macrolide antibiotics, can concentrate in leukocytes and many tissues. Action of clindamycin is primarily against gram-positive organisms such as Staphylococcus, Streptococcus, and gram-positive rods such as Corynebacterium
Clindamycin is primarily used for gram-positive or anaerobic bacterial infections involving the skin, respiratory tract, or oral cavity. Resistance with Staphylococcus may occur. It is effective for some oral infections and anaerobic infections. It also has been used for Mycoplasma infections. Efficacy of clindamycin for treating toxoplasmosis is controversial. Some studies have shown that clindamycin improved clinical signs, but it did not resolve the infection. Another study showed that clindamycin inhibited killing of Toxoplasma organisms by leukocytes.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
執行前須由獸醫師核對鹽型、精確商品與效價標示、物種、感染部位、病原與菌株、培養及感受性、病患腸胃與食道風險、肝腎狀況、神經肌肉用藥、監測、抗菌藥物管理及法域。任何公開數值均不得脫離其商品、物種、感染與研究契約進入通用執行。
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
73%
renal